Month: September 2026

NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) — Global Net Lease, Inc. (“GNL” or the “Company”) (NYSE: GNL/ GNL PRA / GNL PRB / GNL PRD / GNL PRE) announced today that it declared quarterly dividends on its outstanding preferred stock. Specifically, GNL declared (i) a dividend of $0.453125 per share on its 7.25% Series A Cumulative Redeemable Preferred Stock (“Series A Preferred Stock”), payable on October 15, 2026, to holders of record of shares of its Series A Preferred Stock at the close of business on October 2, 2026, (ii) a dividend of $0.4296875 per share on its 6.875% Series B Cumulative Redeemable Perpetual Preferred Stock (“Series B Preferred Stock”) payable on October 15, 2026 to holders of record of shares of its Series B Preferred Stock at the close of business on October 2, 2026, (iii) a dividend of $0.46875 per share on its 7.50% Series D Cumulative Redeemable Perpetual Preferred Stock (“Series D Preferred Stock”) payable on October 15, 2026 to holders of record of shares of its Series D Preferred Stock at the close of business on October 2, 2026, and (iv) a dividend of $0.4609375 per share on its 7.375% Series E Cumulative Redeemable Perpetual Preferred Stock (“Series E Preferred Stock”) payable on October 15, 2026 to holders of record of shares of its Series E Preferred Stock at the close of business on October 2, 2026.

About Global Net Lease, Inc.
Global Net Lease, Inc. (NYSE: GNL) is a publicly traded real estate investment trust that focuses on acquiring and managing a global portfolio of income producing net lease assets across the United States, and Western and Northern Europe. Additional information about GNL can be found on its website at www.globalnetlease.com. 

Important Notice
The statements in this press release that are not historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause the outcome to be materially different. The words such as “may,” “will,” “seeks,” “anticipates,” “believes,” “expects,” “estimates,” “projects,” “potential,” “predicts,” “plans,” “intends,” “would,” “could,” “should” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties and other factors, many of which are outside of the Company’s control, which could cause actual results to differ materially from the results contemplated by the forward-looking statements. These risks and uncertainties include the risks that any potential future acquisition or disposition by the Company is subject to market conditions, capital availability and timing considerations and may not be identified or completed on favorable terms, or at all. Some of the risks and uncertainties, although not all risks and uncertainties, that could cause the Company’s actual results to differ materially from those presented in the Company’s forward-looking statements are set forth in the “Risk Factors” and “Quantitative and Qualitative Disclosures about Market Risk” sections in the Company’s Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and all of its other filings with the U.S. Securities and Exchange Commission, as such risks, uncertainties and other important factors may be updated from time to time in the Company’s subsequent reports. Further, forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise any forward-looking statement to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time, unless required by law.

Contacts:
Investor Relations
Email: investorrelations@globalnetlease.com

NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) — StepStone Private Venture and Growth Fund (“SPRING” or the “Fund”) announced that its Board of Trustees has approved a distribution to shareholders with a record date of September 29, 2026. The distribution is expected to be paid in mid-October 2026 after determination of SPRING’s September 30, 2026 net asset value.

The distribution will be based on the Fund’s tax basis earnings through September 30, 2026, and will represent primarily long-term capital gains.

“We are pleased to issue a September distribution to shareholders following a period of strong fund performance,” said Bob Long, CEO of StepStone Private Wealth Solutions. “This distribution reflects realized gains across the portfolio, underscoring our commitment to delivering long-term value for investors. We remain encouraged by the fund’s investments in next-generation companies positioned to benefit from innovation, as well as the strong capital raise activity in 2026 and low redemption levels under 1%*, demonstrating investors’ continued confidence in the strategy.”

The Fund is finalizing the amounts associated with realized gains and expects to announce the exact distribution amount closer to the record date.

The Fund expects to make its scheduled distribution in December 2026 of the net investment income, if any, earned through December 31, 2026, and net realized capital gains, if any, earned through October 31, 2026.

*As of August 26, 2026. On a quarterly basis, at the discretion of the Board of Trustees, SPRING offers a share repurchase program for up to 2.5% of the Fund’s outstanding Shares per quarter subject to limitations. The Fund is not obligated to redeem any shares, and the Board may modify, suspend or terminate the plan.

Past performance does not guarantee future results.

Important Disclosures
An investment in the Fund involves risks. The Fund should be considered a speculative investment that entails substantial risks, and a prospective investor should invest in the Fund only if it can sustain a complete loss of its investment. Fund shares are illiquid and appropriate only as a long-term investment.

Before investing you should carefully consider the Fund’s investment objectives, risks, charges and expenses. This and other information is in the prospectus, a copy of which may be obtained from StepStone Private Wealth at 704.215.4300 or by visiting stepstonepw.com. An investor should read the prospectus carefully before investing.

This and other information is contained in the Fund’s prospectus, which should be read carefully before investing. StepStone does not provide tax advice. Any information provided regarding tax matters is for informational purposes only and should not be construed as tax advice. Investors and prospective investors should consult their own tax advisors regarding the tax consequences of any investment or transaction. The final character of all distributions paid will be reported to investors on Form 1099‐DIV.

There is no assurance that the Fund will declare a similar distribution in any future period, and the Fund’s distribution rate remains subject to change at the discretion of the Board. Past distributions are not indicative of future distributions or of Fund performance.

This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the expected timing and payment of the distribution. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and the Fund undertakes no obligation to update them except as required by law.

The StepStone Private Venture and Growth Fund is registered as a diversified, closed-end management investment company structured as a tender offer fund.

SPRING is distributed by Distribution Services, LLC which is not affiliated with StepStone Group Private Wealth.

Contacts:

StepStone Private Wealth Operations
spwoperations@stepstonegroup.com

Media
Jordan Niezelski / Maggie Duffy, Edelman
StepStone@edifi-dje.com

BUILT FOR THE WILD: FIELD-TESTED. MADE FOR MORE.

AUSTIN, Texas, Sept. 17, 2026 (GLOBE NEWSWIRE) — YETI Holdings, Inc. (“YETI”) (NYSE: YETI) will host its 2026 Investor Day today in Austin, Texas. Under the theme “Built for the Wild: Field-Tested. Made for More.,” YETI’s leadership team will outline how the Company intends to build on its iconic brand, accelerate innovation, strengthen commercialization and scale a proven international playbook to drive increasingly profitable growth and long-term shareholder value.

Matt Reintjes, Chair of the Board, President and Chief Executive Officer said, “We have spent two decades building a field-tested foundation, and we believe YETI is well positioned to expand what we build, where we sell it and how far our brand can travel. The capabilities beneath the business are stronger, the playbook is clearer and the opportunity is broader. The next chapter for YETI is about building a larger, more global and more durable company, supported by expanding product platforms, improving profitability and strong free cash flow generation. As we enter our next decade, we are focused on four priorities: creating the next billion dollars of sales, building our next billion-dollar product platform, generating a billion dollars of sales outside the United States and delivering more than a billion dollars of cumulative free cash flow. These priorities are underpinned by a clear operating plan and disciplined capital allocation framework, which we believe will drive durable growth and attractive long-term shareholder returns.”

A Focused Strategy Built to Compound
YETI will detail four mutually reinforcing growth engines as part of investor day presentations:

• Build on a strong foundation and extend the brand. Deepen YETI’s relevance in the communities it serves while earning a place in more moments, with more consumers and across more geographies.
• Accelerate Innovation. Apply a repeatable innovation engine to expand product families across Gear & Equipment, Home & Hydration, and Bags & Soft Coolers, with Bags & Soft Coolers becoming YETI’s next billion-dollar platform.
• Power US commercialization. Put the right product in the right place with the right story through sharper consumer vertical strategies, complementary channel expansion, and a more disciplined end-to-end go-to-market process.
• Scale globally. Repeat a proven playbook that builds credibility, activates locally and scales through wholesale, direct-to-consumer and marketplace channels, positioning YETI to generate a billion dollars of International sales.

Long-Term Financial Framework
YETI’s long-term financial algorithm through Fiscal 2030 is the basis for the Company’s long-term financial commitments and is designed to translate diversified sales growth into faster earnings growth and strong free cash flow generation – the majority of which will continue to be returned to shareholders via share repurchases:

Long-Term Metric	Financial Framework
Annual net sales growth	Mid-single-digit to High-single-digit
Annual adjusted operating income growth	High-single-digit to Low-double-digit
Annual adjusted EPS growth	Low-double-digit to High-teens
Cumulative free cash flow (5-year period ending Fiscal 2030)	$1.2 billion to $1.4 billion

The Company intends to fund its highest-return organic growth opportunities, maintain balance-sheet flexibility, selectively pursue tuck-in acquisitions that add capability or speed, and return excess cash to shareholders, primarily through share repurchases. Through Project Upcycle, YETI’s enterprise-wide productivity initiative, the Company has identified approximately $100 million of productivity opportunity across cost of goods sold and operating expenses to help fund growth investments, offset mix pressures, and support sustainable margin expansion.

Fiscal 2026 Outlook Reiterated
YETI is reiterating the Fiscal 2026 outlook most recently provided on August 13, 2026:

Fiscal 2026 Metric	Outlook
Sales growth	7% to 8%
Adjusted operating income growth	10% to 12%
Adjusted operating income as a percentage of sales	14.9%
Adjusted EPS	$2.94 to $3.00
Effective tax rate (GAAP)	24%
Diluted weighted average shares outstanding	75.4 million
Capital expenditures	$60 million to $70 million
Free cash flow	$200 million to $225 million

Investor Day Webcast
Presentations will begin today at 8:00 a.m. Central Time (9:00 a.m. Eastern Time). A live webcast will be available in the investor relations section of YETI’s website at investors.yeti.com. A replay of the event and presentation materials will be available on the website following the event.

About YETI Holdings, Inc.
Headquartered in Austin, Texas, YETI is a global designer, retailer, and distributor of innovative outdoor products. From coolers and drinkware to bags and apparel, YETI products are built to meet the unique and varying needs of diverse outdoor pursuits, whether in the remote wilderness, at the beach, or anywhere life takes you. By consistently delivering high-performing, exceptional products, we have built a strong following of brand loyalists throughout the world, ranging from serious outdoor enthusiasts to individuals who simply value products of uncompromising quality and design. We have an unwavering commitment to outdoor and recreation communities, and we are relentless in our pursuit of building superior products for people to confidently enjoy life outdoors and beyond. For more information, please visit www.YETI.com.

Non-GAAP Financial Measures
This press release includes forward-looking non-GAAP financial measures, including adjusted operating income, adjusted operating income margin, adjusted EPS and free cash flow. YETI does not provide reconciliations of forward-looking non-GAAP measures to the most directly comparable GAAP measures because such reconciliations are not available without unreasonable effort. This is due to the inherent difficulty in forecasting with reasonable certainty certain amounts that are necessary for such reconciliations. For the same reasons, we are unable to forecast with reasonable certainty all deductions and additions needed in order to provide forward-looking GAAP financial measures at this time. The amount of these deductions and additions may be material and, therefore, could result in forward-looking GAAP financial measures being materially different or less than forward-looking non-GAAP financial measures. See “Forward-Looking Statements” below.

Forward-Looking Statements
This press release contains ‘‘forward-looking statements’’ within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current fact included in this press release are forward-looking statements. Forward-looking statements include statements containing words such as “anticipate,” “assume,” “believe,” “can have,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “likely,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “potential,” “seek,” “should,” “target,” “will,” “would,” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operational performance or other events. For example, all statements made regarding long-term strategy, future operating results and financial condition, growth opportunities, productivity initiatives, capital allocation plans, including share repurchases and acquisitions, international expansion, product platform ambitions and the Fiscal 2026 outlook constitute forward-looking statements.
All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that are expected and, therefore, you should not unduly rely on such statements. The risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these forward-looking statements include but are not limited to: (i) economic conditions or consumer confidence in future economic conditions; (ii) our ability to maintain and strengthen our brand and generate and maintain ongoing demand for our products; (iii) our ability to successfully design, develop and market new products; (iv) our ability to effectively manage our growth; (v) our ability to expand into additional consumer markets, and our success in doing so; (vi) the success of our international expansion plans; (vii) our ability to compete effectively in the outdoor and recreation market and protect our brand; (viii) the level of customer spending for our products, which is sensitive to general economic conditions and other factors; (ix) problems with, or loss of, our third-party contract manufacturers and suppliers or an inability to obtain raw materials; (x) fluctuations in the cost and availability of raw materials, equipment, labor, and transportation and subsequent manufacturing delays or increased costs; (xi) adverse changes in international trade policies, tariffs and treaties, including increases in tariff rates and the imposition of additional tariffs; (xii) our ability to accurately forecast demand for our products and our results of operations; (xiii) our relationships with our national, regional, and independent retail partners, who account for a significant portion of our sales; (xiv) risks associated with our direct-to-consumer channel; (xv) substantial fixed costs related to operating retail stores; (xvi) the impact of natural disasters and failures of our information technology on our operations and the operations of our manufacturing partners; (xvii) the integration and use of artificial intelligence; (xviii) our ability to attract and retain skilled personnel and senior management, and to maintain the continued efforts of our management and key employees; (xix) the impact of our indebtedness on our ability to invest in the ongoing needs of our business; and (xx) our ability to successfully execute our share repurchase program and its impact on stockholder value and the volatility of the price of our common stock. For a more extensive list of factors that could materially affect our results, you should read our filings with the United States Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the year ended January 3, 2026, as such filings may be amended, supplemented or superseded from time to time by other reports YETI files with the SEC.
These forward-looking statements are made based upon detailed assumptions and reflect management’s current expectations and beliefs. While YETI believes that these assumptions underlying the forward-looking statements are reasonable, YETI cautions that it is very difficult to predict the impact of known factors, and it is impossible for YETI to anticipate all factors that could affect actual results. The forward-looking statements included here are made only as of the date hereof. YETI undertakes no obligation to publicly update or revise any forward-looking statement as a result of new information, future events, or otherwise, except as required by law.

Investor Relations Contact:
Arvind Bhatia, CFA
Investor.relations@yeti.com

Media Contact:
YETI Holdings, Inc. Media Hotline
Media@yeti.com

Companies commercialize scale manufacturability of 800G to 1.6T PICs in external pluggable and CPX MSA compliant NPO socket pluggable solutions built on PH18DA platform designed for high-density monolithic laser integration, SOAs, modulators and detectors

MIGDAL HAEMEK, Israel, and TEL AVIV, Israel, September 17, 2026 – Tower Semiconductor (NASDAQ/TASE: TSEM), the leading foundry for high-value analog semiconductor solutions, and NewPhotonics®, a fabless semiconductor delivering innovative photonic IC chip solutions, today announced high-volume shipment of laser-integrated serviceable optical engines designed to meet the urgent and growing demand for high-bandwidth, energy-efficient optical interconnects in artificial intelligence infrastructure.

The PIC optical engine chips support OEM solutions ranging from FRO/LRO/LPO and Extra-Dense Packaged Optics (XPO) pluggable transceiver modules and Near-Packaged Optics (NPO) socket pluggable applications. Shipping volume production PICs today support data rates from 800G to 1.6T, with future volume manufacturing planned at 6.4T NPO solutions suitable for scale-out and scale-up architectures.

The collaboration leverages the high-volume PH18DA silicon photonics (SiPho) technology platform featuring heterogeneously integrated InP components enabling monolithic integration of lasers, semiconductor optical amplifiers (SOAs), modulators, and photodetectors on a single photonic integrated circuit. This highly integrated, optical-domain focused approach reduces complexity and manufacturing variability to supply better yield, reliability, and time-to-market with a leading-edge photonic device.

Volume shipment of NewPhotonics NPG102 PIC products for 800G and 1.6T feature 200G-per-lane designs and heterogeneously integrated lasers on a monolithic PIC enable customers to leverage optical signal processing in a unified architecture that delivers power efficiency, bandwidth density, and manufacturing consistency. The CPX-MSA compliant NPC505 chipsets for 6.4T will begin volume shipment in 1H27.

“The next phase of AI infrastructure demands optical connectivity that scales in both production and performance,” said Doron Tal, SVP and GM of NewPhotonics. “With Tower, we are translating laser-integrated photonics into a practical choice and volume availability. By combining our optical chip design with their manufacturing platform, we are first to bring higher-bandwidth, energy-efficient highly integrated systems to the OEM customer and data center market.”

“We are excited to see our vision of integrating lasers with high-performance photonic integrated circuits come to fruition through scale-ready solutions optimized for FRO/LRO and NPO architectures,” said Dr. Ed Preisler, Vice President and General Manager, RF Business Unit, Tower Semiconductor. “NewPhotonics is a valued partner and the first to bring heterogenous laser-integrated optical engines on the PH18DA platform into high-volume production, marking an important milestone in scaling optical connectivity for next-generation AI infrastructure.”

Both companies will participate in the upcoming ECOC 2026, September 21–23 at FYCMA in Malaga, Spain, with representatives available for meetings during the event.

To learn more about Tower Semiconductor’s advanced silicon photonics (SiPho) platform and RF & HPA technology offerings, visit booth #C1014. Additional information is also available on the Company’s website: here.

NewPhotonics will showcase the NPG102 and NPC505 PIC products in Pavilion 2 stand #2009. Additional information about the company as well as scheduling for ECOC meetings and demo sessions can be accessed at the company’s ECOC event page

About Tower Semiconductor

Tower Semiconductor Ltd. (NASDAQ/TASE: TSEM), the leading foundry of high-value analog semiconductor solutions, provides technology, development, and process platforms for its customers in growing markets such as consumer, industrial, automotive, mobile, infrastructure, medical and aerospace and defense. Tower Semiconductor focuses on creating a positive and sustainable impact on the world through long-term partnerships and its advanced and innovative analog technology offering, comprised of a broad range of customizable process platforms such as SiPho, SiGe, BiCMOS, mixed-signal/CMOS, RF CMOS, CMOS image sensor, non-imaging sensors, displays, and integrated power management (BCD and 700V). Tower Semiconductor also provides world-class design enablement for a quick and accurate design cycle as well as process transfer services including development, transfer, and optimization, to IDMs and fabless companies. To provide multi-fab sourcing and extended capacity for its customers, Tower Semiconductor currently owns one operating facility in Israel (200mm), two in the U.S. (200mm), and two in Japan (200mm and 300mm) which it owns through its 51% holdings in TPSCo and shares a 300mm facility in Agrate, Italy with STMicroelectronics. For more information, please visit: www.towersemi.com.

Safe Harbor Regarding Forward-Looking Statements
This press release includes forward-looking statements, which are subject to risks and uncertainties. Actual results may vary from those projected or implied by such forward-looking statements. A complete discussion of risks and uncertainties that may affect the accuracy of forward-looking statements included in this press release or which may otherwise affect Tower’s business is included under the heading “Risk Factors” in Tower’s most recent filings on Forms 20-F, F-3, F-4 and 6-K, as were filed with the Securities and Exchange Commission (the “SEC”) and the Israel Securities Authority. Tower does not intend to update, and expressly disclaim any obligation to update, the information contained in this release.

About NewPhotonics

NewPhotonics is a fabless semiconductor delivering innovative optical-first silicon photonic product and technology innovation for AI-era hyperscaler, neo-cloud and data center interconnect that enables market disrupting energy efficiency and production simplicity and volume of FRO/LRO/LPO and NPO pluggables as well as advanced co-packaged optics solutions. In a highly integrated and system approach to design, the company offers laser integrated PICs for scale-out and scale-up photonic interconnect, the OSPic^® all-optical signal processor engine, and the industry-first Syncra^™ powered by Niox^™ heaterless MRM CPO platform with zero-loss monitoring and real-time calibration. Visit www.newphotonics to learn more.
                                                
Tower Semiconductor Company Contact: Orit Shahar | +972-74-7377440 | oritsha@towersemi.com
Tower Semiconductor Investor Relations Contact: Liat Avraham | +972-4-6506154 | liatavra@towersemi.com

NewPhotonics Press Contact:
press.relations@newphotonics.com +972 3 614-3147  

Attachment

• Tower_NewPhotonics_NPO_PR_FINAL_09172026.docx

VANCOUVER, British Columbia, Sept. 17, 2026 (GLOBE NEWSWIRE) — Cambria Gold Mines Inc. (TSXV: CAMB; OTCQX: CAMVF) (“Cambria” or the “Company”) announces that due to the opportunity to realize significant value for shareholders as a potential Tier 1 asset, the Company will retain its ownership in the Mt. Margaret copper and gold porphyry deposit located in Washington State (“Mt. Margaret”), deferring the proposed spinout. Based on ongoing discussions with strategic partners, feedback from Cambria’s investors and the strong fundamentals for copper, the Company believes significantly more value can be added by advancing Mt. Margaret as a significant asset within the portfolio, in addition to the Premier Gold Mine Complex and the Red Mountain Gold Deposit located in the Golden Triangle of British Columbia. Cambria will provide updates on the continued drilling, engineering and construction advancements at the Premier Mine Complex and the Red Mountain Gold Deposit in the near future.

To support Cambria’s new vision of advancing Mt. Margaret, the Company is pleased to announce the immediate addition of an exceptional US-based director to the Cambria board: Kim Colloton. Additionally, Cleve Rueckert, previously announced as Vice-President (USA), will assume the role of Vice-President of Corporate Development for Cambria. As previously announced, Asa East, Vice-President of Exploration (USA), David Thomas, Vice-President Projects (USA) and Orla Abrahams, Manager, Stakeholder Relations (USA) will continue in their current roles.

“We see the opportunity to build an exceptional growth-oriented company at Cambria, anchored by near-term gold production at the Premier Gold Mine Complex in Canada and a potential Tier 1 copper deposit at Mt. Margaret. With over one square kilometer of outcropping mineralization at surface, open for expansion in most directions and at depth below 500 meters, the Mt. Margaret deposit represents a unique opportunity in the United States. Through systematic goals including: permitting milestones, infill and exploration drilling, Mineral Resource Estimates and Economic Studies, we feel that we can add substantial value for our shareholders by keeping our portfolio together,” said Robert McLeod, CEO of Cambria Gold Mines. “Our Company will be supported by the highly accretive addition of US-based team members, including our new director Retired Major General Kim Colloton, as well as ex-Barrick Vice-President Cleve Rueckert.”

“I am excited about this expanded opportunity, working with an exceptional team focused on building something special,” said Cleve Rueckert. “We think there is substantial value embedded in Cambria’s portfolio of assets and I look forward to helping unlock that value for the benefit of our stakeholders, importantly the communities where we work, our employees and our shareholders.”

Cambria’s US-based management team continues to advance permit applications and environmental studies supporting additional exploration drilling at Mt. Margaret in the near future. The Company has also begun engagement with local communities and county, state, federal and Tribal representatives regarding Mt. Margaret. These early discussions are intended to establish open communication, understand stakeholder priorities, and inform the Company’s environmental, technical and socioeconomic work as the project is evaluated. Additionally, Cambria has completed relogging and geological modelling of available core from the deposit, reaffirming its view of Mt. Margaret as a unique and exceptional copper-gold porphyry deposit.

Board and Management Additions:

Major General (Retired) Kim Colloton, Director

Major General (Retired) Kim Colloton, a senior executive leader with over 30 years of distinguished service in the United States Army, has consistently delivered strategic and enterprise-wide impact across complex global organizations and high-stakes missions. Most recently, she served as the Deputy Chief of Engineers and Deputy Commanding General for the U.S. Army Corps of Engineers (USACE) in Washington, D.C. In this role, she provided strategic leadership and oversight for a $90-billion global portfolio and a workforce of 38,000 civilian and military professionals. She drove performance and accountability across resource management, contracting, engineering and construction, human capital, and network modernization, ensuring the effective and efficient delivery of critical capabilities.

Prior to her current role, Major General Colloton served as the Deputy Commanding General for Military and International Programs. In this capacity, she led the worldwide execution of U.S. military design and construction, real estate, environmental services, and foreign military sales programs that supported key partners and allies. She also advanced interagency engineering solutions for organizations such as the Department of Homeland Security and the Department of Veterans Affairs, thereby strengthening mission readiness across government.

Kim’s leadership experience spans multiple command positions, with her most prominent role being the Commanding General of the United States Army Corps of Engineers’ Transatlantic Division. In this capacity, she directed intricate expeditionary engineering operations to support the Department of Defense, U.S. Central Command, and U.S. Special Operations Command across the Middle East and Central Asia. Her operational experience also includes multiple extended deployments to Afghanistan and Iraq, where she led teams in dynamic and high-risk environments.

Additionally, Kim commanded the United States Army Corps of Engineers’ South Pacific Division, overseeing a ten-state region encompassing the Western and Southwestern United States. She collaborated closely with state and federal leaders to deliver mission-critical military construction, significant civil works initiatives such as coastal storm damage mitigation and flood risk reduction, water resource planning, environmental programs, and regional emergency preparedness and disaster response operations. Kim has also held key staff positions, including Chief of the Mission Assurance & Protection Division on the Joint Staff in Washington, D.C.

Kim holds a Bachelor of Architecture and Building Science from Rensselaer Polytechnic Institute, a Master of Science in Civil Engineering from Stanford University, and a Master of Science in National Resource Strategy with a concentration in strategic materials from the National Defense University’s Eisenhower School. She also completed a fellowship at the RAND Corporation’s Arroyo Center. Currently, she serves as a Non-Executive Director for Bayan Mining and Minerals Limited, an Australian Securities Exchange-listed company, and as a Corporate Advisory Board Member for Strategic Solutions Unlimited, located in Fayetteville, North Carolina.

Cleveland Rueckert, Vice-President of Corporate Development

Cleveland Rueckert is a seasoned finance professional with twenty years of capital markets experience spanning investment management, equity research and investor relations. Cleve most recently served as Vice President, Head of Investor Relations at Barrick Mining Corporation, one of the world’s leading gold producers, where he helped the investment community understand the value of the world-class Fourmile project. Prior to joining Barrick, Cleve had many years of progressively senior roles at investment banks, primarily in equity research at UBS, concluding as an Executive Director covering the Metals & Mining and Paper & Packaging sectors in both North and South America. He began his career working at Birinyi Associates with the legendary investment strategist and Salomon Brothers alumnus, Laszlo Birinyi.

Cleve holds an MBA from the NYU Stern School of Business and a BA from the University of Vermont. He brings a rare combination of analytical rigor, media fluency, and relationship-building to his work. Beyond his professional life, Cleve serves on the Board of Directors of the YMCA of Greater New York, as Vice Chair of the Finance Committee and as a Director and member of the Investment Committee of the Cleveland H. Dodge Foundation.

Termination of Arrangement with ECC Ventures

The Company is terminating the binding term sheet with ECC Ventures 4 Corp. (TSXV: ECCF.P) (“ECC4”) and cancelling the proposed spin-out transaction with ECC4 and concurrent financing, previously announced on July 7, 2026.

Equity Grant

Cambria further announces the granting of incentive stock options (“Options”) to purchase an aggregate of 2,800,000 common shares of the Company (a “Common Share”) to new directors, officers, employees and consultants of the Company in accordance with the Company’s Stock Option Plan, which was approved by the shareholders of the Company at its annual meeting of shareholders held on June 29, 2026.  Each Option is exercisable into one Common Share at an exercise price of $0.90. The Options vest over eighteen months, with 25% vesting on the date of grant and an additional 25% vesting every six months thereafter, expiring September 16, 2031.

In addition, the Company has granted 700,000 restricted share units (“RSUs“) and 180,000 deferred share units (“DSUs”) to new directors, officers, employees and consultants of the Company. Each of the RSUs and DSUs will vest equally over three years, with the first vesting date occurring September 16, 2027. Upon vesting, each RSU and DSU represents the right to receive one Common Share in accordance with the Restricted Share Unit Plan / Deferred Share Unit Plan, which was approved by the shareholders of the Company at its annual meeting of shareholders held on June 29, 2026.

About the Mt. Margaret Copper-Gold Deposit

The Mt. Margaret deposit is a calc-alkaline porphyry deposit hosting high-grade copper, gold, and molybdenum mineralization located approximately 22 km southwest of Randle, Washington State. The Mt. Margaret Project is primarily located on patented federal mineral claims that are held by Cambria and the United States Federal Government Bureau of Land Management (“BLM”) and located on Forest Service land. Through its US entity, Ascot USA Inc. (“Ascot US”), Cambria controls 50% mineral rights of select patented claims centered over the deposit with the Federal Government controlling the remaining 50%, as well as other patents in the area. Cambria also controls 100% interest in 184 lode claims surrounding the property. The Company has been advancing discussions with various US Federal Government Departments, including the BLM, regarding future direction for the deposit.

This porphyry system was discovered and actively explored by Duval Corporation (“Duval”) from 1971-1980, completing a total of 20,729m over 105 diamond drill holes (Taylor, 1980)¹. In 2010, Cambria’s predecessor, Ascot Resources Ltd., completed 4,880m of infill diamond drilling over 10 holes, which confirmed and expanded the mineralized zones defined by Duval’s drilling (See Cambria’s News Releases dated October 13, November 3, November 23, and December 1, 2010 and January 12, 2011).

A historical mineral resource was completed by Duval for the Mt. Margaret deposit, totaling 577Mt grading 0.36% Cu, 0.24 g/t Au, 0.011% Mo, and 1.58 g/t Ag (Taylor, 1980)¹. This historic estimate predates the implementation of National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI-43-101”) guidelines and is not compliant with currently accepted reserve and resource classifications as set forth by the Canadian Institute of Mining and Metallurgy, August 20, 2000 (CIM Guidelines) or the United States Securities and Exchange Commission’s Regulation Subpart 1300 of Regulation S-K (“S-K 1300”). Furthermore, uncertainty regarding cut-off grade, metal prices, modelling methodology, or other parameters and assumptions used in the Duval work could impact the reliability of the historic estimation. A qualified person has not done sufficient work to classify the historical estimate as current mineral resources or mineral reserves and the Company is not treating the historical estimate as current mineral resources or mineral reserves. Further work including quality assurance / quality control procedures, geological modelling, and assay certificate and collar validation by a Qualified Person would be required to produce a NI-43-101 or an S-K 1300 compliant resource. There are no guarantees that this additional work would confirm the historical resource estimate defined by Duval.

Qualified Person
The scientific and technical information within this news release has been reviewed and approved by Asa East, CPG, Vice President Exploration (USA) for Cambria Gold Mines Inc. and a non-independent Qualified Person as defined by National Instrument 43-101. Mr. East is a Certified Professional Geologist in good standing with the American Institute of Professional Geologists (AIPG).

About Cambria Gold Mines

Cambria Gold Mines is a Canadian mining company headquartered in Vancouver, British Columbia, and its shares trade on the TSXV under the ticker CAMB and on the OTCQX Market with the ticker CAMVF. Cambria is the 100% owner of the Premier Gold mine and Red Mountain Gold Project that are located on Nisga’a Nation Treaty Lands, in the prolific Golden Triangle of northwestern British Columbia. For more information about the Company, please refer to the Company’s profile on SEDAR+ at www.sedarplus.ca or visit the Company’s web site at www.cambriagold.com.

On behalf of the Board of Directors of Cambria Gold Mines Inc.

Robert McLeod
CEO and Director 

For further information contact:

Email: info@cambriagold.com
Phone: 778-725-1060

and:

Sam Brezden
Email: sam.brezden@cambriagold.com
Phone: 236-838-1840

and:

Cleve Rueckert
Email: crueckert@cambriagold.com

Or visit:

https://cambriagold.com/

Cautionary Statements:

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cautionary Statement Regarding Forward-Looking Information

All statements and other information contained in this press release about anticipated future events may constitute forward-looking information under Canadian securities laws (“forward-looking statements”). Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “targeted”, “outlook”, “on track” and “intend” and statements that an event or result “may”, “will”, “should”, “could”, “would” or “might” occur or be achieved and other similar expressions. All statements, other than statements of historical fact, included herein are forward-looking statements, including statements relating to: the advancement of Mt. Margaret and the anticipated creation of value; the results and timing of continued drilling, engineering and construction advancements at the Premier Mine Complex and the Red Mountain Gold Deposit; and future plans, development and operations of the Company. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements, risks relating to negative operating cash flows of the Company; business and economic conditions in the mining industry generally; fluctuations in commodity prices and currency exchange rates; environmental compliance; risks related to outstanding debt; uncertainty of estimates and projections relating to development, production, costs and expenses, and health, safety and environmental risks; uncertainties relating to interpretation of drill results and the geology, continuity and grade of mineral deposits; the need to obtain additional financing to finance operations and uncertainty as to the availability and terms of future financing; social media and reputation; negative publicity; human rights; business objectives; shortage of personnel; health and safety; the possibility of delay in future plans and uncertainty of meeting anticipated program milestones; claims and legal proceedings; information systems and cyber security; internal controls; violation of anti-bribery or corruption laws; competition; tax considerations; compliance with listing standards; enforcement of civil liabilities; financing requirement risks; market price volatility of the common shares; uncertainty as to timely availability of permits and other governmental approvals; the need for exchange approval, and other regulatory approvals and other risk factors as detailed from time to time in each party’s respective filings with Canadian securities regulators, available on such party’s profile on SEDAR+ at www.sedarplus.ca. Forward-looking statements are based on assumptions made with regard to: market conditions remaining favourable; the estimated costs associated with the care and maintenance plans; the tax rate applicable to the Company; future commodity prices; the grade of mineral resources and mineral reserves; labor and materials costs increasing on a basis consistent with the Company’s current expectations, the ability of the Company to convert inferred mineral resources to other categories; the ability of the Company to reduce mining dilution; the ability to reduce capital costs; the ability of the Company to raise additional financing; currency exchange rates being approximately consistent with current levels, compliance with the covenants in Cambria’s credit agreements; exploration plans; and general marketing, political, business and economic conditions. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. Although the parties believe that the expectations reflected in such forward-looking statements and/or information are reasonable, undue reliance should not be placed on forward-looking statements since the parties can give no assurance that such expectations will prove to be correct. The parties do not undertake any obligation to update forward-looking statements, other than as required by applicable laws. The forward-looking information contained in this press release is expressly qualified by this cautionary statement.

_{¹ Taylor, J.D., 1980, Margaret project status report: Duval Corporation report (unpublished). Available in the Washington Department of National Resources Archives}

Global GIL Recognition Spotlights Apeloa’s End-to-End “API + Drug Product” Integration, Advanced Technology Platforms, and Its Compliance Track Record in Regulated Markets

SHANGHAI, Sept. 17, 2026 (GLOBE NEWSWIRE) — Apeloa Pharmaceutical Co., Ltd. (Apeloa; SZSE: 000739.SZ), a leading contract development and manufacturing organization (CDMO) and technology-driven pharmaceutical manufacturer, announced that it has been awarded the “2026 Global CDMO Company of the Year Award” by growth advisory firm Frost & Sullivan. Presented at the 20th Frost & Sullivan Growth, Innovation & Leadership (GIL) Global Summit, the accolade positions Apeloa as a benchmark for excellence in small-molecule drug development, advanced synthesis platforms, and commercial supply chain resilience.

Frost & Sullivan Honors Apeloa Pharmaceutical Co., Ltd. with the “2026 Global CDMO Company of the Year Award”

The Global CDMO Company of the Year Award represents Frost & Sullivan’s Best Practices Awards program, recognizing companies that lead their industries through visionary innovation, operational excellence, superior customer care, and substantial global market performance. Notably, Apeloa is the first China-headquartered CDMO in years to earn this global cross-category recognition, highlighting its strategic evolution into a trusted global development partner.

• Fully Integrated “API + Drug Product” Synergy: Streamlined progression from registered starting materials (RSM) and advanced intermediates to APIs and finished dosage forms across 8 manufacturing sites.

• High-Barrier Tech Platforms: Deep expertise across 8 technology platforms, including flow chemistry, peptide, conjugate library service, synthetic biology & biocatalysis, high-potency compound, crystallization & particle engineering, oligonucleotide synthesis and preparation & purification.

• Global Compliance: Pristine regulatory track record, with 20^th successful US FDA inspection since 2006, alongside official audit compliance with the EU EMA/EDQM, Japan PMDA, and China NMPA.

• Global Innovation Network: Boston, Shanghai, and Hengdian R&D centers seamlessly integrated with scalable commercial-scale manufacturing backbones to provide agile global support.

Pioneering Advanced Chemistries and Complex Modalities

As modern drug discovery pivots toward higher structural complexity, Apeloa has moved beyond traditional chemical manufacturing into solving industry “bottleneck” synthetic challenges. The company’s specialized flow chemistry platform materially reduces thermal and safety hazards in energetic reactions, dramatically shortening scale-up cycles, boosting batch reproducibility, and improving manufacturing efficiency. Concurrently, Apeloa’s dedicated platforms for peptide, antibody-drug conjugate (ADC), proteolysis-targeting chimeras (PROTACs), and high-potency compounding help global biotech partners reduce risk in complex candidate development from preclinical candidate selection to commercial launch.

Global Supply Chain Certainty and Quality Excellence

Serving more than 700 pharmaceutical partners worldwide, including multiple top-20 global pharmaceutical companies. Apeloa generated over 44% of its revenue from overseas markets. Through sustained multi-site smart automation, real-time digital monitoring, and comprehensive data integrity controls, Apeloa provides uninterrupted supply chain security for vital cardiovascular, anti-infective, CNS, and oncology pipelines.

“The CDMO industry has fundamentally evolved: global biopharmaceutical innovators no longer need just a contract manufacturing facility, but an agile, highly synchronized external CMC partner who truly understands their scientific logic and can solve the most challenging synthetic hurdles,” stated George Cai, Senior Vice President and Head of the CDMO Business Unit at Apeloa, during his keynote at CMC-China 2026 on September 4, where Apeloa was also distinguished with five premier industry honors, including the ‘2026 CDMO Best Service Provider Award.’

“Over the past six years, Apeloa has successfully transformed from a traditional API manufacturer into a research-driven, end-to-end CDMO. Whether solving complex synthetic chemistries through flow chemistry, peptides, and ADC platforms, or navigating multi-country regulatory pathways, our commitment is to achieve complete resonance with our clients, delivering speed, uncompromised quality, and cost efficiency to accelerate life-saving, affordable medicines to patients worldwide.”

Rigorous Independent Industry Evaluation

According to Frost & Sullivan’s award evaluation, the Global CDMO Company of the Year Award is adjudicated through an extensive assessment of market performance, technology innovation, global compliance, and commercial delivery. The independent judging panel recognized Apeloa’s standout performance in bridging advanced green chemistry and high-barrier technology platforms with regulatory-compliant, large-scale manufacturing, highlighting its end-to-end capabilities across intermediates, APIs, and finished formulations.

About Apeloa

As a global CDMO leader, Apeloa (SZSE: 000739.SZ) offers end-to-end pharmaceutical solutions, excelling in small molecules, peptides, ADCs, and more. With 8 manufacturing sites, 3 R&D centers, and 8 advanced technical platforms worldwide, Apeloa advances customer molecules to market. Guided by its mission of Technology for Health and backed by a trusted quality system certified by regulators, Apeloa empowers partners to accelerate drug development and commercial production, enabling global clients in expediting the delivery of affordable medications.

Website: https://www.apeloa.com/en

LinkedIn: https://www.linkedin.com/company/apeloa-pharmaceutical-co-ltd

CDMO Business Inquiries: info_cdmo@apeloa.com

Media Relations: coco.li@apeloa.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/34d5e08f-9f34-45ec-96d8-df8a3a8b6960

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN
    GB00BLDRH360

Issuer Name
    OSB GROUP PLC

UK or Non-UK Issuer

    UK

2. Reason for Notification

    An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name
    Lorentzweiler Adjacent Partners S.C.Sp.

City of registered office (if applicable)
    Howald

Country of registered office (if applicable)

    Luxembourg

4. Details of the shareholder

    Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

    City of registered office (if applicable) Country of registered office (if applicable)

5. Date on which the threshold was crossed or reached

    15-Sep-2026

6. Date on which Issuer notified
    16-Sep-2026

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached

% of voting rights through financial

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

	to shares (total of 8.A)	instruments (total of 8.B 1 + 8.B 2)
Resulting situation on the date on which threshold was crossed or reached	5.087900	0.000000	5.087900	17238397
Position of previous notification (if applicable)	4.019900	0.000000	4.019900

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
GB00BLDRH360	17238397	0	5.087900	0.000000
Sub Total 8.A	17238397		5.087900%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights
Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation
2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the

% of voting rights through financial instruments if it equals or is

Total of both if it equals or is higher than the notifiable threshold

		notifiable threshold	higher than the notifiable threshold
Alan Waxman		3.096900		3.096900%
Alan Waxman	Sixth Street Partners Management Company, L.P.	3.096900		3.096900%
Alan Waxman	TAO Finance 3, LLC	1.858100		1.858100%
Alan Waxman	Beacon Finance 3, LLC	0.619400		0.619400%
Alan Waxman	Sixth Street Madrone Strategic Holdings I, L.P	0.619400		0.619400%
Alan Waxman	Lorentzweiler Adjacent Partners, S.C.Sp (acting through its general partner, Lorentzweiler Adjacent Investments, S.à r.l.)	3.096900		3.096900%
Alan Waxman		4.019900		4.019900%
Alan Waxman	Sixth Street Partners Management Company, L.P.	4.019900		4.019900%
Alan Waxman	TAO Finance 3, LLC	2.411900		2.411900%
Alan Waxman	Beacon Finance 3, LLC	0.804000		0.804000%

Alan Waxman	Sixth Street Madrone Strategic Holdings I, L.P	0.804000		0.804000%
Alan Waxman	Lorentzweiler Adjacent Partners, S.C.Sp (acting through its general partner, Lorentzweiler Adjacent Investments, S.à r.l.)	4.019900		4.019900%
Alan Waxman		5.087900		5.087900%
Alan Waxman	Sixth Street Partners Management Company, L.P.	5.087900		5.087900%
Alan Waxman	TAO Finance 3, LLC	3.052800		3.052800%
Alan Waxman	Beacon Finance 3, LLC	1.017600		1.017600%
Alan Waxman	Sixth Street Madrone Strategic Holdings I, L.P	1.017600		1.017600%
Alan Waxman	Lorentzweiler Adjacent Partners, S.C.Sp (acting through its general partner, Lorentzweiler Adjacent Investments, S.à r.l.)	5.087900		5.087900%

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held If date does not apply, explain below

11.    Additional Information

12.    Date of Completion
        16-Sep-2026

13.    Place Of Completion
        Luxembourg

RECORDATI ANNOUNCES THE WINNER OF THE 12TH EDITION OF THE ARRIGO RECORDATI PRIZE FOR SCIENTIFIC RESEARCH

• The 2026 Award, open to early career investigators from around the world, was dedicated to advancing research in paediatric oncology, focused on sarcomas
• Paediatric sarcomas are among the leading causes of cancer-related death in children, yet there has been little innovation in treatment progress over the past 40 years
• Dr. Laura Broutier has been awarded the €250,000 research grant for her DISARMS project on fusion-negative rhabdomyosarcoma
• The project aims to uncover the mechanisms that allow tumour cells to survive chemotherapy and prevent relapse and metastasis, with the ultimate goal of identifying new, low-toxicity therapeutic approaches

Milan, 17 September 2026 – Recordati S.p.A today announced Dr. Laura Broutier as the winner of the 12^th edition of the International Prize for Scientific Research Arrigo Recordati, dedicated this year to advancing research in paediatric oncology, with a specific focus on sarcomas.

At the 58^th Annual SIOP Congress, in Texas, Dr. Broutier was awarded the €250,000 research grant for her project, “DISARMS – Disrupting Invasion, Stemness And Resistance in RhabdoMyoSarcoma by targeting dormant persister cells.”

The winning project was selected by an independent Review Committee of internationally recognised experts following the assessment of research proposals submitted by early career investigators from around the world.

Established in 2000 in memory of the Italian pharmaceutical entrepreneur Arrigo Recordati, the Prize aims to promote scientific research and inspire biomedical discoveries benefiting people worldwide. Since 2019, reflecting Recordati’s commitment to rare diseases, the Prize has been dedicated to the promotion and recognition of excellence in orphan disease treatment research.

“It is a privilege to award the 12th Arrigo Recordati Prize to Dr. Laura Broutier and her team, and to support research with the potential to make a meaningful difference for children affected by these devastating diseases,” said Andrea Recordati, Chairman of Recordati. “Paediatric sarcomas remain an area of significant unmet need, where progress in treatment has been limited for decades. Supporting outstanding researchers and innovative science is one way we can contribute to advancing knowledge and, ultimately, to improving outcomes for patients and their families.”

Paediatric sarcomas

Paediatric sarcomas are a diverse group of rare cancers arising in bone and soft tissues and are among the leading causes of cancer-related death in children. Despite advances in the understanding of their biology, there has been limited innovation in treatment over the past 40 years.

Advancing understanding of the pathophysiology of paediatric sarcomas is critical to developing targeted therapies that are both effective and tolerable, while limiting treatment-related toxicity. Translational research that bridges laboratory discoveries with clinical applications is therefore essential to developing new therapeutic approaches and improving outcomes for children affected by these diseases.

The winning project: DISARMS

Fusion-negative rhabdomyosarcoma is the most common soft-tissue sarcoma of children and young adults, yet survival has not improved in four decades and treatment toxicity precludes further dose escalation. The mechanisms allowing tumour cells to survive chemotherapy and later drive relapse and metastasis remain poorly understood.

Combining patient-derived organoids, single-cell technologies, and genetic engineering, we have uncovered a dormant, drug-tolerant persister cell state whose signature predicts patient survival in independent cohorts. Building on this foundation, the DISARMS project aims to decode how this cell state couples chemoresistance to an invasive, pro-metastatic programme, and to exploit its vulnerabilities in rational, low-toxicity drug combinations to eliminate the cells conventional chemotherapy spares. As dormant persister programmes are increasingly recognised across cancer types, the framework developed here may extend beyond rhabdomyosarcoma.

2026 Award Winner: Dr. Laura Broutier

Dr. Laura Broutier is an Inserm researcher and group leader at the Cancer Research Center of Lyon, in the “Childhood Cancers & Cell States” team led by Dr. Marie Castets and Prof. Jean-Yves Blay. After a PhD on cancer cell death resistance and a postdoc in Cambridge, pioneering the first liver tumour-derived organoids, she redirected this expertise toward paediatric cancers — rare diseases with almost no dedicated models. Her group now grows 3D tumoroids directly from children’s biopsies, including sarcomas, developing innovative approaches to decipher and bypass the molecular and cellular processes that drive treatment resistance, relapse and dissemination.

Dr. Broutier leads the DISARMS project together with a multidisciplinary team combining expertise in patient-derived organoid modeling, single-cell multiomics, computational biology, cancer cell metabolism and translational paediatric oncology. Dr. Maëlle Broustal, a third-year PhD student in biology and bioinformatics who is directly involved in the project, received the Award on Dr. Broutier’s behalf at the 2026 Award Ceremony.

“I am deeply honoured that the DISARMS project has been selected for the 2026 Arrigo Recordati Prize,” said Dr. Laura Broutier. “Our research seeks to understand how a small population of tumour cells can survive chemotherapy and later drive relapse and metastasis. With the support of this Prize, we hope to identify vulnerabilities that can be translated into rational, low-toxicity therapeutic approaches, with the ultimate goal of improving outcomes for children and young adults with rhabdomyosarcoma. I am also particularly grateful for the recognition of the team behind this work.”

The Award Ceremony was held in San Antonio, Texas, during the SIOP Congress.

The International Prize for Scientific Research Arrigo Recordati

The Prize is an international award that aims to promote scientific research and inspire biomedical discoveries benefiting people worldwide. It was established in 2000 in memory of Arrigo Recordati, who strongly believed in the power of scientific research to drive the growth of the pharmaceutical industry and provide products beneficial to public health and individual well-being. His legacy continues to inspire a new generation of researchers — driven by the belief that scientific discovery is the true engine of progress in healthcare.

Over the last almost 20 years, Recordati has developed, produced and marketed medicines for the treatment of rare diseases through Recordati Rare Diseases, dedicated entirely to serving patients globally living with rare conditions and focused on key treatment areas including rare metabolic diseases, endocrinology and hema-oncology. From 2019, to reflect our commitment, the Prize is dedicated to the promotion and recognition of excellence in orphan disease treatment research.

Contacts
recordatiprize2026@recordati.com

Media Relations
Laura Conti conti.l@recordati.it	Rebecca Kerr rebecca.kerr@recordati.com

Recordati is an international pharmaceutical Group listed on the Italian Stock Exchange (XMIL: REC), with roots dating back to a family-run pharmacy in Northern Italy in the 1920s. We are uniquely structured to provide treatments across specialty and primary care and rare diseases. Our fully integrated operations span clinical development, manufacturing of active ingredients and finished products, commercialization and licensing. We operate in approximately 150 countries across EMEA, the Americas and APAC, with around 4,700 employees. We believe that health is a fundamental right, not a privilege. Today, our purpose “Unlocking the full potential of life” aims to empower individuals to live life to the fullest, from common conditions to the rarest.